Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRXBiotechnology
-$0.01 today
- Market cap
- $3.85B
- Beta
- 0.74
- P/E (TTM)
- 17.3
- EPS (TTM)
- $1.81
Volume 0.00M
Average 2.17M
CPRX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $59.56M fell 0.8% year over year, ahead of the -22.2% change in trailing-twelve-month free cash flow. Sequentially, it rose 32.8% from the prior quarter. Over 3 fiscal years it compounded at +21.6% a year.
Context
- Free cash flow amounted to 35.4% of revenue in FY2025, down 13.2 pp from a year earlier.
- Free cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -0.8% holds above the trailing-twelve-month pace of -22.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 208.61M USD
- Year-over-year change
- -12.8%
- 4-year CAGR
- +36.9%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 208.61M | -12.8% |
| FY2024 | 2024-12-31 | 239.25M | +286.8% |
| FY2023 | 2023-12-31 | 61.86M | -46.7% |
| FY2022 | 2022-12-31 | 116.02M | +95.5% |
| FY2021 | 2021-12-31 | 59.35M | — |
Free Cash Flow vs competitors
How CPRX compares with its peers on the latest reported figures
- CPRX's LTM Mar 2026 free cash flow of $208.13M is the 5th largest of the 9 companies compared; the peer median is $224.02M.
- Its year-over-year change of -22.2% is the 6th highest of 9, against a peer median of -7.4%.
- Free cash flow amounts to 34.9% of revenue for CPRX, versus a peer median of 238.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $384.73M | -4.7% | +6.3% | 582.5% | |
| LTM Jun 2026 | $372.77M | +4.8% | +138.8% | 238.9% | |
| LTM Jun 2026 | $354.27M | -10.1% | +46.3% | 645.8% | |
| LTM Sep 2026 | $309.25M | +12.6% | +31.0% | 54254.0% | |
| LTM Mar 2026 | $208.13M | -22.2% | +21.6% | 34.9% | |
| LTM Jun 2026 | $183.1M | +175.4% | +64.6% | 21.8% | |
| LTM Jun 2026 | $138.8M | -28.0% | +69.6% | — | |
| LTM Mar 2026 | $87.93M | -67.2% | -6.8% | 39.0% | |
| LTM Jun 2026 | $24.03M | -71.0% | -37.5% | 7.8% | |
| Peer median (excluding CPRX) | $224.02M | -7.4% | +38.6% | 238.9% | |
Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 39.48M | 83.08M | 71.41M | 163.89M | 214.33M |
| Depreciation & Amortization | 192K | 1.24M | 32.88M | 37.77M | 37.87M |
| Deferred Income Tax | 9.32M | 4.94M | (17.82M) | (9.39M) | (6.85M) |
| Stock-Based Compensation | 6.07M | 7.91M | 14.25M | 22.25M | 24.78M |
| Change in Working Capital | 5.02M | 13.73M | (37.32M) | 30.91M | (60.9M) |
| Accounts Receivables | (632K) | (3.82M) | (43.08M) | (11.96M) | (61M) |
| Inventory | (3.22M) | 1.07M | (4.74M) | (3.9M) | (18.09M) |
| Accounts Payables | (1.49M) | 1.21M | 10.82M | 1.8M | (5.39M) |
| Other Working Capital | 10.36M | 15.28M | (330K) | 44.98M | 23.59M |
| Other Non-Cash Items | 287K | 5.16M | 80.2M | (5.63M) | (563K) |
| Operating Cash Flow | 60.37M | 116.05M | 143.6M | 239.81M | 208.67M |
| Capital Expenditures | (1.02M) | (29K) | (81.74M) | (556K) | (58K) |
| Acquisitions (Net) | 0 | 10M | 0 | 0 | 0 |
| Purchases of Investments | (10M) | (10M) | (13.47M) | 0 | 0 |
| Sales of Investments | 0 | 19.24M | 0 | 0 | 0 |
| Other Investing Activities | 0 | (10M) | (279.81M) | 0 | 0 |
| Investing Cash Flow | (11.02M) | 9.21M | (293.5M) | (556K) | (58K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 4.1M | 9.57M | 2.79M | 141M | 14.67M |
| Common Stock Repurchased | (12.09M) | (6.91M) | 0 | (296K) | (25.3M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (153K) | (968K) | (13.65M) | (39K) | (6.36M) |
| Financing Cash Flow | (8.14M) | 1.69M | (10.86M) | 140.67M | (16.99M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.21M | 126.95M | (160.76M) | 379.92M | 191.62M |
| Free Cash Flow | 59.35M | 116.02M | 61.86M | 239.25M | 208.61M |
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
Intrinsic Alpha fair value
Locked
Current Price
$31.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.